Eli Lilly Expands US Presence with San Diego Lab Amid Tariff-Friendly Environment

Eli Lilly has opened the Lilly Gateway Labs in San Diego, supporting up to 15 life sciences companies and aligning with U.S. tariff changes encouraging domestic pharmaceutical production. Amgen is investing $650 million in Puerto Rico to expand biologics drug manufacturing, creating 750 new jobs. Lilly's financial performance is robust, with strong revenue growth and expanding margins. However, the company has a higher reliance on debt financing and trades with a premium valuation.

Eli Lilly and Company has announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, marking a significant expansion in its network of shared innovation hubs designed to support early-stage biotechnology companies Eli Lilly and Company Announces the Official Opening of Its Newest Lilly Gateway Labs Site in San Diego, California^[1]. The new facility, developed by and operated in partnership with Alexandria Real Estate Equities Inc., is located on the One Alexandria Square Megacampus in Torrey Pines. LGL San Diego features 82,514 square feet of flexible designed laboratory and office space to accommodate up to 15 life sciences companies and more than 250 employees of LGL-based companies.

The companies based in Gateway Labs represent a diverse array of therapeutic approaches and disease areas, aligned with and outside of Lilly's core focus areas. LGL San Diego has already attracted several early-stage biotechs leveraging next-generation modalities to work on some of the body's most complex systems and difficult-to-treat diseases. Lilly Gateway Labs is one component of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and LillyuneLab which together support biotech innovation by providing access to strategic capital, lab space, and technology, and research and development capabilities including advanced AI models.

The opening of the first Gateway Labs site in December 2019 has already attracted more than $2 billion in capital supporting more than 50 therapeutics and platforms currently in development. Gateway Labs has five global sites across San Francisco, San Diego, Boston, and Beijing to meet the needs of emerging biotechs in thriving life science communities.

Separately, Amgen has announced a $650 million expansion of its manufacturing facility in Juncos, Puerto Rico, which is expected to create approximately 750 new jobs Amgen to invest $650m in Puerto Rico manufacturing expansion^[2]. The investment will support increased drug production capabilities and integrate advanced technologies throughout the operations process. This expansion aligns with Amgen’s strong financial performance, including 12.88% revenue growth over the last twelve months and an EBITDA of $16.15 billion. The company cited the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025 as facilitating its ability to invest domestically in manufacturing and research.

Eli Lilly reported quarterly earnings of $6.31 per share, surpassing estimates and showing a year-over-year revenue growth of 37.6% Beacon Investment Advisory Services Inc. Has $17.54 Million Stake in Eli Lilly and Company $LLY^[3]. The company has a higher reliance on debt financing and trades with a premium valuation, but its robust financial performance and strategic investments in biotech innovation position it well for future growth.